288 related articles for article (PubMed ID: 7806691)
1. The brief psychiatric rating scale: effect of scaling system on clinical response assessment.
Thompson PA; Buckley PF; Meltzer HY
J Clin Psychopharmacol; 1994 Oct; 14(5):344-6. PubMed ID: 7806691
[TBL] [Abstract][Full Text] [Related]
2. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
[TBL] [Abstract][Full Text] [Related]
3. Violence and schizophrenia: clozapine as a specific antiaggressive agent.
Buckley P; Bartell J; Donenwirth K; Lee S; Torigoe F; Schulz SC
Bull Am Acad Psychiatry Law; 1995; 23(4):607-11. PubMed ID: 8639988
[TBL] [Abstract][Full Text] [Related]
4. Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia.
Kelly DL; Feldman S; Boggs DL; Gale E; Conley RR
Compr Psychiatry; 2010; 51(3):298-302. PubMed ID: 20399340
[TBL] [Abstract][Full Text] [Related]
5. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics.
Henderson DC; Goff DC
J Clin Psychiatry; 1996 Sep; 57(9):395-7. PubMed ID: 9746446
[TBL] [Abstract][Full Text] [Related]
6. Predictors of clinical outcome in schizophrenic patients responding to clozapine.
Mauri MC; Volonteri LS; Dell'Osso B; Regispani F; Papa P; Baldi M; Bareggi SR
J Clin Psychopharmacol; 2003 Dec; 23(6):660-4. PubMed ID: 14624196
[TBL] [Abstract][Full Text] [Related]
7. [A four-dimensional model of chronic schizophrenia based on the factorial structure of the Positive and Negative Syndrome Scale (PANSS). A study of a group of 153 chronic schizophrenic patients and comparison with the factorial structure of the BPRS].
Loas G; Noisette C; Legrand A; Delahousse J
Encephale; 1997; 23(1):10-8. PubMed ID: 9172962
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of clozapine with a second antipsychotic--a meta-analysis of randomized, placebo-controlled studies.
Taylor DM; Smith L
Acta Psychiatr Scand; 2009 Jun; 119(6):419-25. PubMed ID: 19245679
[TBL] [Abstract][Full Text] [Related]
9. Equipercentile linking of the BPRS and the PANSS.
Leucht S; Rothe P; Davis JM; Engel RR
Eur Neuropsychopharmacol; 2013 Aug; 23(8):956-9. PubMed ID: 23433639
[TBL] [Abstract][Full Text] [Related]
10. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia.
Semiz UB; Cetin M; Basoglu C; Ebrinc S; Uzun O; Herken H; Balibey H; Algul A; Ates A
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1330-6. PubMed ID: 17618026
[TBL] [Abstract][Full Text] [Related]
11. Clinical response to clozapine treatment of 11 chronic patients in a state psychiatric hospital.
Herman M
Aust N Z J Ment Health Nurs; 1997 Sep; 6(3):129-33. PubMed ID: 9384012
[TBL] [Abstract][Full Text] [Related]
12. Clinical effects of a randomized switch of patients from clozaril to generic clozapine.
Kluznik JC; Walbek NH; Farnsworth MG; Melstrom K
J Clin Psychiatry; 2001; 62 Suppl 5():14-7; discussion 23-4. PubMed ID: 11305843
[TBL] [Abstract][Full Text] [Related]
13. Clozapine withdrawal symptoms after change to sertindole in a schizophrenic patient.
Berecz R; Glaub T; Kellermann M; de la Rubia A; Llerena A; Degrell I
Pharmacopsychiatry; 2000 Jan; 33(1):42-4. PubMed ID: 10721883
[TBL] [Abstract][Full Text] [Related]
14. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study.
Dursun SM; Szemis A; Andrews H; Reveley MA
J Psychiatry Neurosci; 1999 Nov; 24(5):453-5. PubMed ID: 10586536
[TBL] [Abstract][Full Text] [Related]
15. [Clozapine and treatment of negative symptoms].
Lançon C; Farisse J; Llorca PM
Encephale; 1997 Sep; 23 Spec No 4():7-11. PubMed ID: 9417403
[TBL] [Abstract][Full Text] [Related]
16. Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol.
Sa AR; Hounie AG; Sampaio AS; Arrais J; Miguel EC; Elkis H
Compr Psychiatry; 2009; 50(5):437-42. PubMed ID: 19683614
[TBL] [Abstract][Full Text] [Related]
17. [Quality of life of schizophrenic patients and clozapine].
Raoul Y; Manesse P; Delage M
Encephale; 1997 Sep; 23 Spec No 4():12-6. PubMed ID: 9417398
[TBL] [Abstract][Full Text] [Related]
18. [Depressive symptoms and biogenic amines as predictors of treatment response in schizophrenic illnesses in childhood and adolescence].
Fleischhaker C; Schulz E; Remschmidt H
Z Kinder Jugendpsychiatr Psychother; 1998 Dec; 26(4):235-43. PubMed ID: 9880833
[TBL] [Abstract][Full Text] [Related]
19. [Long-term clinical experience with clozapine].
Gelly F; Chambon O; Marie-Cardine M
Encephale; 1997; 23(5):385-96. PubMed ID: 9453932
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia.
Lee KU; Jeon YW; Lee HK; Jun TY
Hum Psychopharmacol; 2009 Aug; 24(6):447-52. PubMed ID: 19606454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
